Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Patricia A. Creel"'
Autor:
Michael A. Carducci, Angelo M. De Marzo, Robin Gurganus, Daniel J. George, Phillip G. Febbo, Helen Fedor, Antonio Jimeno, Alan W. Partin, Luciana Schultz, Roula Albadine, Ting Wang, S. Lindsay Davis, Kelly Mundy, Patricia A. Creel, David P. Wood, Susan Halabi, Michelle A. Rudek, George J. Netto, Andrew J. Armstrong
Purpose: Given discrepancies between preclinical and clinical observations of mammalian target of rapamycin (mTOR) inhibition in prostate cancer, we sought to determine the pharmacodynamic effects of the mTOR/TORC1 inhibitor rapamycin in men with int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d89e2c593bd06ba355c5eb1dd80c5a7
https://doi.org/10.1158/1078-0432.c.6519354
https://doi.org/10.1158/1078-0432.c.6519354
Autor:
Michael A. Carducci, Angelo M. De Marzo, Robin Gurganus, Daniel J. George, Phillip G. Febbo, Helen Fedor, Antonio Jimeno, Alan W. Partin, Luciana Schultz, Roula Albadine, Ting Wang, S. Lindsay Davis, Kelly Mundy, Patricia A. Creel, David P. Wood, Susan Halabi, Michelle A. Rudek, George J. Netto, Andrew J. Armstrong
Supplementary Data from A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a4fa2460be48a93fb41a6b517b0c3
https://doi.org/10.1158/1078-0432.22442682.v1
https://doi.org/10.1158/1078-0432.22442682.v1
Autor:
Patricia A, Creel
Publikováno v:
Clinical journal of oncology nursing. 18(6)
The current standard of care for treating metastatic renal cell carcinoma is sequential therapy with vascular endothelial growth factor-targeted agents (i.e., axitinib, bevacizumab, pazopanib, sorafenib, and sunitinib) and mammalian target of rapamyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::40a839c652eb2d4b5b91a0bfab5d1fb8
https://pubmed.ncbi.nlm.nih.gov/25427704
https://pubmed.ncbi.nlm.nih.gov/25427704
